Phase III clinical trial results presented on 11 and 12 December at the American Society of Hematology (ASH) annual meeting for two CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapies – Bristol Myers Squibb Company’s Breyanzi (lisocabtagene maraleucel) and Gilead Sciences, Inc. subsidiary Kite Pharma, Inc.’s Yescarta (axicabtagene ciloleucel) – are being hailed as practice-changing for adults with large B-cell lymphoma (LBCL) who were refractory or relapsed within 12 months of first-line treatment.
Each of the CAR-T products, both of which are approved after two or more prior lines of treatment, quadrupled event-free...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)